31
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      PReS-FINAL-2218: Treatment of colchicines resistant FMF: experience of a pediatric center in Turkey

      abstract
      1 , , 1 , 1 , 1 , 1
      Pediatric Rheumatology Online Journal
      BioMed Central
      20th Pediatric Rheumatology European Society (PReS) Congress
      25-29 September 2013

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction Familial Mediterrenean fever (FMF) is an autoinflammmatory disorder which result from mutations in MEFV gene and characterized by dysregulated inflammasome activation and IL1β secretion. At least 5% of FMF patients do not respond to colchicine. Objectives To evaluate the characteristics of colchicine resistant children and adolescents and present our initial treatment results. Methods FMF resistance was defined as having ≥2 attacks in a month and persistently high CRP and SAA levels during the attack free period, in spite of adequate colchine dose. All patients were homozygous or compound heterozygotes for MEFV mutations. One patient who is on anakinra treatment has HIDS mutation as well. All continued colchicine treatment at a mean dose of 0,04 ± 0,01 mg/kg. Results Eleven patients with mean age of 12,7 ± 7,7 years (median 14, ranging 1,5-23 years) were studied. These patients were on colchicine treatment for a mean of 5,5 ± 4,2 years. A total of 7 patients were started anakinra, however since 2 had local reactions and 2 was unresponsive; they were switched to canakinumab. At this time a total of 8 patients are now being treated with canakinumab with a mean duration of 10,8 ± 6,8 months and 3 patients with anakinra with a mean duration of 19,6 months and they all have normal acute phase reactants. In one patient initially etanercept was used, she initially responded well but after 6 months, she became resistant and switched to anakinra. She was also well with anakinra but after 8 months, she also became resistant to anakinra despite increasing dose up to 6 mg/kg and started canakinumab. Now she has been well with canakinumab for 6 months. Except two patients who had local reactions with anakinra, there were no side effects. Conclusion Anti IL1 treatment is beneficial in FMF patients who are resistant to colchicine and can be used safely. These patients may also become resistant to anti TNF or anakinra treatment. Disclosure of interest None declared.

          Related collections

          Author and article information

          Conference
          Pediatr Rheumatol Online J
          Pediatr Rheumatol Online J
          Pediatric Rheumatology Online Journal
          BioMed Central
          1546-0096
          2013
          5 December 2013
          : 11
          : Suppl 2
          : P208
          Affiliations
          [1 ]Pediatric Nephrology-Rheumatology Department, Hacettepe University Faculty of Medicine, Ankara, Turkey
          Article
          1546-0096-11-S2-P208
          10.1186/1546-0096-11-S2-P208
          4044487
          f1f1c079-884f-43bc-b75e-df9854ef0b3b
          Copyright © 2013 Kara Eroglu et al.; licensee BioMed Central Ltd.

          This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

          20th Pediatric Rheumatology European Society (PReS) Congress
          Ljubljana, Slovenia
          25-29 September 2013
          History
          Categories
          Poster Presentation

          Pediatrics
          Pediatrics

          Comments

          Comment on this article